Drug Trial Radar · NCT05487170
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Last checked: Nov 19, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jul 12, 2022
Primary completion
Jun 1, 2025
Study completion Sep 1, 2025
Sponsor
- Lead sponsor
- Ranok Therapeutics (Hangzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.
Conditions
- Advanced Solid Tumor
- DLBCL
Interventions
RNK05047Drug
RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence of DLTsTime frame: through 1 cycle/4 weeks
- Part 1: Incidence of TEAEsTime frame: through study completion, an average of 1 year
- Part 2: Incidence of TEAEsTime frame: through study completion, an average of 1 year
- Part 2: Objective response rate (ORR) based on RECIST 1.1/RECIL 2017Time frame: through study completion, an average of 1 year
- Part 2: Duration of response (DoR) based on RECIST 1.1/RECIL 2017Time frame: through study completion, an average of 1 year
- Part 2: Progression-free Survival (PFS) based on RECIST 1.1/RECIL 2017Time frame: through study completion, an average of 1 year
- Part 2: Disease Control Rate (DCR) based on RECIST 1.1/RECIL 2017Time frame: through study completion, an average of 1 year
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Emory University Winship Cancer Institute
Atlanta, Georgia · Completed
Norton Cancer Institute
Louisville, Kentucky · Completed
Weill Cornell - NY Presbyterian Hospital
New York, New York · Completed
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.